Advances in small-molecule therapy for managing angina pectoris in the elderly

References

• Benjamin EJ, Muntner P, Alonso A, et al. Heart disease and stroke statistics-2019 update: a report from the American heart association. Circulation. 2019 Mar 5;139(10):e56–e528.
   PubMed Web of Science ®Google Scholar
• Brorsson B, Bernstein SJ, Brook RH, et al. Quality of life of patients with chronic stable angina before and four years after coronary revascularisation compared with a normal population. Heart. 2002 Feb;87(2):140–145.
   PubMed Web of Science ®Google Scholar
• Qintar M, Spertus JA, Gosch KL, et al. Effect of angina under-recognition on treatment in outpatients with stable ischaemic heart disease. Eur Heart J Qual Care Clin Outcomes. 2016;2(3):208–214.
   PubMed Web of Science ®Google Scholar
• Shafiq A, Arnold SV, Gosch K, et al. Patient and physician discordance in reporting symptoms of angina among stable coronary artery disease patients: insights from the angina prevalence and provider evaluation of angina relief (APPEAR) study. Am Heart J. 2016;175:94–100.
   PubMed Web of Science ®Google Scholar
• National Instutes of Health, National Cancer Institute. NCI dictionary of cancer terms. Small-molecule drug. [cited 2019 April 21]. Available from: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/small-molecule-drug.
   Google Scholar
• Arnold SV, Grodzinsky A, Gosch KL, et al. Predictors of physician under-recognition of angina in outpatients with stable coronary artery disease. Circ Cardiovasc Qual Outcomes. 2016 9;Sep(5):554–559.
   Google Scholar
• Afilalo J, Karunananthan S, Eisenberg MJ, et al. Role of frailty in patients with cardiovascular disease. Am J Cardiol. 2009 Jun 1;103(11):1616–1621.
   PubMed Web of Science ®Google Scholar
• Gharacholou SM, Roger VL, Lennon RJ, et al. Comparison of frail patients versus nonfrail patients >/=65 years of age undergoing percutaneous coronary intervention. Am J Cardiol. 2012 Jun 1;109(11):1569–1575.
   PubMed Web of Science ®Google Scholar
• Newman AB, Gottdiener JS, McBurnie MA, et al. Associations of subclinical cardiovascular disease with frailty. J Gerontol A Biol Sci Med Sci. 2001 Mar;56(3):M158–66.
   PubMed Web of Science ®Google Scholar
• Woods NF, LaCroix AZ, Gray SL, et al. Frailty: emergence and consequences in women aged 65 and older in the Women’s Health Initiative Observational Study. J Am Geriatr Soc. 2005 Aug;53(8):1321–1330.
   PubMed Web of Science ®Google Scholar
• Kleipool EE, Hoogendijk EO, Trappenburg MC, et al. Frailty in older adults with cardiovascular disease: cause, effect or both? Aging Dis. 2018 Jun;9(3):489–497.
   PubMed Web of Science ®Google Scholar
• Duncker DJ, Bache RJ. Regulation of coronary blood flow during exercise. Physiol Rev. 2008 Jul;88(3):1009–1086.
   PubMed Web of Science ®Google Scholar
• Kones R. Recent advances in the management of chronic stable angina I: approach to the patient, diagnosis, pathophysiology, risk stratification, and gender disparities. Vasc Health Risk Manag. 2010 Aug;9(6):635–656.
   Google Scholar
• Ford TJ, Corcoran D, Berry C. Stable coronary syndromes: pathophysiology, diagnostic advances and therapeutic need. Heart. 2018 Feb;104(4):284–292.
   PubMed Web of Science ®Google Scholar
• Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention. A report of the American college of cardiology foundation/American heart association task force on practice guidelines and the society for cardiovascular angiography and interventions. J Am Coll Cardiol. 2011 Dec 6;58(24):e44–122.
   PubMed Web of Science ®Google Scholar
• Mallika V, Goswami B, Rajappa M. Atherosclerosis pathophysiology and the role of novel risk factors: a clinicobiochemical perspective. Angiology. 2007 Oct-Nov;58(5):513–522.
   PubMed Web of Science ®Google Scholar
• Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med. 2007 Feb 22;356(8):830–840.
   PubMed Web of Science ®Google Scholar
• Marinescu MA, Loffler AI, Ouellette M, et al. Coronary microvascular dysfunction, microvascular angina, and treatment strategies. JACC Cardiovasc Imaging. 2015 Feb;8(2):210–220.
   PubMedGoogle Scholar
• Crea F, Bairey Merz CN, Beltrame JF, et al.. Mechanisms and diagnostic evaluation of persistent or recurrent angina following percutaneous coronary revascularization. Eur Heart J. 2019 Jan 4. DOI:10.1093/eurheartj/ehy857 . [Epub ahead of print]
   Google Scholar
• Brunton TL. On the use of nitrite of amyl in angina pectoris. Lancet. 1867 July 27;90(2291):97–98.
   Google Scholar
• Beta-Blocker Heart Attack Trial Research Group.A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results. Jama. 1982 Mar 26;247(12):1707–1714.
   PubMed Web of Science ®Google Scholar
• MERIT-HF Study Group. Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999 Jun 12;353(9169):2001–2007.
   PubMed Web of Science ®Google Scholar
• CIBIS-II Investigators and Health Economics Group.The cardiac insufficiency bisoprolol study II (CIBIS-II): a randomised trial. Lancet. 1999 Jan 2;353(9146):9–13.
   PubMed Web of Science ®Google Scholar
• Freemantle N, Cleland J, Young P, et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. Bmj. 1999 Jun 26;318(7200):1730–1737.
   PubMed Web of Science ®Google Scholar
• Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996 May 23;334(21):1349–1355.
   PubMed Web of Science ®Google Scholar
• Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001 May 31;344(22):1651–1658.
   PubMed Web of Science ®Google Scholar
• Shibata MC, Flather MD, Wang D. Systematic review of the impact of beta blockers on mortality and hospital admissions in heart failure. Eur J Heart Fail. 2001 Jun;3(3):351–357.
   PubMed Web of Science ®Google Scholar
• Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005 Feb;26(3):215–225.
   PubMed Web of Science ®Google Scholar
• Study to Evaluate Effect of Nebivolol on Angina in Women With Microvascular Disease (NIRVANA). cited 2019 January 16. Available from: https://clinicaltrials.gov/ct2/show/NCT01665508
   Google Scholar
• Winchester DE, Pepine CJ. Usefulness of Beta blockade in contemporary management of patients with stable coronary heart disease. Am J Cardiol. 2014 Nov 15;114(10):1607–1612.
   PubMed Web of Science ®Google Scholar
• Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012 Dec 18;126(25):3097–3137.
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery diseaseThe International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. Jama. 2003 Dec 3;290(21):2805–2816.
   PubMed Web of Science ®Google Scholar
• Vogele A, Johansson T, Renom-Guiteras A, et al. Effectiveness and safety of beta blockers in the management of hypertension in older adults: a systematic review to help reduce inappropriate prescribing. BMC Geriatr. 2017 Oct 16;17(Suppl 1):224.
   PubMedGoogle Scholar
• Lopez-Sendon J, Swedberg K, McMurray J, et al. Expert consensus document on beta-adrenergic receptor blockers. Eur Heart J. 2004 Aug;25(15):1341–1362.
   PubMed Web of Science ®Google Scholar
• Lanza GA, Careri G, Crea F. Mechanisms of coronary artery spasm. Circulation. 2011 Oct 18;124(16):1774–1782.
   PubMed Web of Science ®Google Scholar
• Shorikova D, Shorikov E Peculiarities of pharmacotherapy of stable angina in elderly patients. E-Journal Cardiol Pract 2017 Aug 2 [cited 2018 Dec 11];15(12). Avilable from: https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-15/peculiarities-of-pharmacotherapy-of-stable-angina-in-elderly-patients.
   Google Scholar
• Kim JH, Zamorano J, Erdine S, et al. Reduction in cardiovascular risk using proactive multifactorial intervention versus usual care in younger (< 65 years) and older (>/= 65 years) patients in the CRUCIAL trial. Curr Med Res Opin. 2013 May;29(5):453–463.
   PubMed Web of Science ®Google Scholar
• Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation. 2000 Sep 26;102(13):1503–1510.
   PubMed Web of Science ®Google Scholar
• Cao X, Nakamura Y, Wada T, et al. Comparison of anti-anginal effect of cilnidipine with those of nicardipine and nifedipine in the vasopressin-induced angina model of rats. Heart Vessels. 2016 Dec;31(12):2045–2052.
   PubMed Web of Science ®Google Scholar
• Chandra KS, Ramesh G. The fourth-generation calcium channel blocker: cilnidipine. Indian Heart J. 2013 Dec;65(6):691–695.
   PubMedGoogle Scholar
• Takahara A Cilnidipine: a new generation Ca channel blocker with inhibitory action on sympathetic neurotransmitter release. Cardiovasc Ther. Summer 2009;27(2):124–139.
   PubMed Web of Science ®Google Scholar
• Boden WE, Finn AV, Patel D, et al. Nitrates as an integral part of optimal medical therapy and cardiac rehabilitation for stable angina: review of current concepts and therapeutics. Clin Cardiol. 2012 May;35(5):263–271.
   PubMed Web of Science ®Google Scholar
• Wei J, Wu T, Yang Q, et al. Nitrates for stable angina: a systematic review and meta-analysis of randomized clinical trials. Int J Cardiol. 2011 Jan 7;146(1):4–12.
   PubMed Web of Science ®Google Scholar
• Tarkin JM, Kaski JC. Nicorandil and long-acting nitrates: vasodilator therapies for the management of chronic stable angina pectoris. Eur Cardiol. 2018 Aug;13(1):23–28.
   PubMed Web of Science ®Google Scholar
• Hall R, Chong C. A double-blind, parallel-group study of amlodipine versus long-acting nitrate in the management of elderly patients with stable angina. Cardiology. 2001;96(2):72–77.
   PubMed Web of Science ®Google Scholar
• Takahashi J, Nihei T, Takagi Y, et al. Prognostic impact of chronic nitrate therapy in patients with vasospastic angina: multicentre registry study of the Japanese coronary spasm association. Eur Heart J. 2015 Jan 21;36(4):228–237.
   PubMed Web of Science ®Google Scholar
• Ambrosio G, Del Pinto M, Tritto I, et al. Chronic nitrate therapy is associated with different presentation and evolution of acute coronary syndromes: insights from 52,693 patients in the global registry of acute coronary events. Eur Heart J. 2010 Feb;31(4):430–438.
   PubMed Web of Science ®Google Scholar
• Hasenfuss G, Maier LS. Mechanism of action of the new anti-ischemia drug ranolazine. Clin Res Cardiol. 2008 Apr;97(4):222–226.
   PubMed Web of Science ®Google Scholar
• Montalescot G, Sechtem U, Achenbach S, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European society of cardiology. Eur Heart J. 2013 Oct;34(38):2949–3003.
   PubMed Web of Science ®Google Scholar
• Chaitman BR, Skettino SL, Parker JO, et al. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004 Apr 21;43(8):1375–1382.
   PubMed Web of Science ®Google Scholar
• Rich MW, Crager M, McKay CR. Safety and efficacy of extended-release ranolazine in patients aged 70 years or older with chronic stable angina pectoris. Am J Geriatr Cardiol. 2007 Jul-Aug;16(4):216–221.
   PubMedGoogle Scholar
• Salazar CA, Basilio Flores JE, Veramendi Espinoza LE, et al. Ranolazine for stable angina pectoris. Cochrane Database Syst Rev. 2017 Feb;8(2):CD011747.
   Google Scholar
• Bairey Merz CN, Handberg EM, Shufelt CL, et al. A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve. Eur Heart J. 2016 May 14;37(19):1504–1513.
   PubMed Web of Science ®Google Scholar
• Rambarat CA, Elgendy IY, Handberg EM, et al. Late sodium channel blockade improves angina and myocardial perfusion in patients with severe coronary microvascular dysfunction: women’s ischemia syndrome evaluation-coronary vascular dysfunction ancillary study. Int J Cardiol. 2019 Feb;1(276):8–13.
   Google Scholar
• Borer JS, Fox K, Jaillon P, et al. Antianginal and antiischemic effects of ivabradine, an I(f) inhibitor, in stable angina: a randomized, double-blind, multicentered, placebo-controlled trial. Circulation. 2003 Feb 18;107(6):817–823.
   PubMed Web of Science ®Google Scholar
• Koester R, Kaehler J, Meinertz T. Ivabradine for the treatment of stable angina pectoris in octogenarians. Clin Res Cardiol. 2011 Feb;100(2):121–128.
   PubMed Web of Science ®Google Scholar
• Tardif JC, Ponikowski P, Kahan T, et al. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur Heart J. 2009 Mar;30(5):540–548.
   PubMed Web of Science ®Google Scholar
• Werdan K, Ebelt H, Nuding S, et al. Ivabradine in combination with beta-blocker improves symptoms and quality of life in patients with stable angina pectoris: results from the ADDITIONS study. Clin Res Cardiol. 2012 May;101(5):365–373.
   PubMed Web of Science ®Google Scholar
• Muller-Werdan U, Stockl G, Ebelt H, et al. Ivabradine in combination with beta-blocker reduces symptoms and improves quality of life in elderly patients with stable angina pectoris: age-related results from the ADDITIONS study. Exp Gerontol. 2014 Nov;59:34–41.
   PubMed Web of Science ®Google Scholar
• Fox K, Ford I, Steg PG, et al. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014 Sep 18;371(12):1091–1099.
   PubMed Web of Science ®Google Scholar
• Simpson D, Wellington K. Nicorandil: a review of its use in the management of stable angina pectoris, including high-risk patients. Drugs. 2004;64(17):1941–1955.
   PubMed Web of Science ®Google Scholar
• Iona Study Group. Effect of nicorandil on coronary events in patients with stable angina: the impact of nicorandil in angina (IONA) randomised trial. Lancet. 2002 Apr 13;359(9314):1269–1275.
   PubMed Web of Science ®Google Scholar
• Izumiya Y, Kojima S, Kojima S, et al. Long-term use of oral nicorandil stabilizes coronary plaque in patients with stable angina pectoris. Atherosclerosis. 2011 Feb;214(2):415–421.
   PubMed Web of Science ®Google Scholar
• Wallis RM, Corbin JD, Francis SH, et al. Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am J Cardiol. 1999 Mar 4;83(5A):3C–12C.
   PubMed Web of Science ®Google Scholar
• Webb DJ, Freestone S, Allen MJ, et al. Sildenafil citrate and blood-pressure-lowering drugs: results of drug interaction studies with an organic nitrate and a calcium antagonist. Am J Cardiol. 1999 Mar 4;83(5A):21C–28C.
   PubMed Web of Science ®Google Scholar
• Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov. 2006 Aug;5(8):689–702.
   PubMed Web of Science ®Google Scholar
• Schwartz BG, Levine LA, Comstock G, et al. Cardiac uses of phosphodiesterase-5 inhibitors. J Am Coll Cardiol. 2012 Jan 3;59(1):9–15.
   PubMed Web of Science ®Google Scholar
• Sacks HS, Ancona-Berk VA, Berrier J, et al. Dipyridamole in the treatment of angina pectoris: a meta-analysis. Clin Pharmacol Ther. 1988 Jun;43(6):610–615.
   PubMed Web of Science ®Google Scholar
• Stewart RB, Marks RG, Padgett PD, et al. A longitudinal evaluation of dipyridamole drug use in an ambulatory elderly population. Chest. 1995 Apr;107(4):1049–1052.
   PubMed Web of Science ®Google Scholar
• Picano E. Pisa study group. Dipyridamole in chronic stable angina pectoris; a randomized, double blind, placebo-controlled, parallel group study. Eur Heart J. 2001 Oct;22(19):1785–1793.
   PubMed Web of Science ®Google Scholar
• Jagathesan R, Rosen SD, Foale RA, et al. Effects of long-term oral dipyridamole treatment on coronary microcirculatory function in patients with chronic stable angina: A substudy of the persantine in stable angina (PISA) study. J Cardiovasc Pharmacol. 2006 Sep;48(3):110–116.
   PubMed Web of Science ®Google Scholar
• Chong CR, Sallustio B, Horowitz JD. Drugs that affect cardiac metabolism: focus on perhexiline. Cardiovasc Drugs Ther. 2016 Aug;30(4):399–405.
   PubMed Web of Science ®Google Scholar
• Horowitz JD, Mashford ML. Perhexiline maleate in the treatment of severe angina pectoris. Med J Aust. 1979 Jun 2;1(11):485–488.
   PubMed Web of Science ®Google Scholar
• Dawes P, Moulder C. Perhexiline hepatitis and HLA-B8. Lancet. 1982 Jul 10;2(8289):109.
   PubMed Web of Science ®Google Scholar
• Fraser DM, Campbell IW, Miller HC. Peripheral and autonomic neuropathy after treatment with perhexiline maleate. Br Med J. 1977 Sep 10;2(6088):675–676.
   PubMedGoogle Scholar
• Sallustio BC, Westley IS, Morris RG. Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose. Br J Clin Pharmacol. 2002 Aug;54(2):107–114.
   PubMed Web of Science ®Google Scholar
• Cole PL, Beamer AD, McGowan N, et al. Efficacy and safety of perhexiline maleate in refractory angina. A double-blind placebo-controlled clinical trial of a novel antianginal agent. Circulation. 1990 Apr;81(4):1260–1270.
   PubMed Web of Science ®Google Scholar
• Stewart S, Voss DW, Northey DL, et al. Relationship between plasma perhexiline concentration and symptomatic status during short-term perhexiline therapy. Ther Drug Monit. 1996 Dec;18(6):635–639.
   PubMed Web of Science ®Google Scholar
• Chrusciel P, Rysz J, Banach M. Defining the role of trimetazidine in the treatment of cardiovascular disorders: some insights on its role in heart failure and peripheral artery disease. Drugs. 2014 Jun;74(9):971–980.
   PubMed Web of Science ®Google Scholar
• Danchin N, Marzilli M, Parkhomenko A, et al. Efficacy comparison of trimetazidine with therapeutic alternatives in stable angina pectoris: a network meta-analysis. Cardiology. 2011;120(2):59–72.
   PubMed Web of Science ®Google Scholar
• Marazzi G, Gebara O, Vitale C, et al. Effect of trimetazidine on quality of life in elderly patients with ischemic dilated cardiomyopathy. Adv Ther. 2009 Apr;26(4):455–461.
   PubMed Web of Science ®Google Scholar
• Fox K, Garcia MA, Ardissino D, et al. Guidelines on the management of stable angina pectoris: executive summary: the task force on the management of stable angina pectoris of the European society of cardiology. Eur Heart J. 2006 Jun;27(11):1341–1381.
   PubMed Web of Science ®Google Scholar
• Effect of Trimetazidine on the Improvement of Coronary Microvascular Dysfunction in Patients With INOCA(Ischemia and no Obstructive Coronary Artery Disease) (T-MICRO). [cited 2019 February 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT03504202
   Google Scholar
• Trimetazidine as an Adjunct to Enhance Clopidogrel Response (TRACER). [cited 2019 February 4]. Available from: https://clinicaltrials.gov/ct2/show/NCT03603249. .
   Google Scholar
• Trimetazidine in Myocardial Injury After Percutaneous Coronary Intervention in Patients With Angina and Diabetes (Trimeta). cited 2019 February 4. Available from: https://clinicaltrials.gov/ct2/show/NCT03715582
   Google Scholar
• Feng Y, LoGrasso PV, Defert O, et al. Rho kinase (ROCK) inhibitors and their therapeutic potential. J Med Chem. 2016 Mar 24;59(6):2269–2300.
   PubMed Web of Science ®Google Scholar
• Vicari RM, Chaitman B, Keefe D, et al. Efficacy and safety of fasudil in patients with stable angina: a double-blind, placebo-controlled, phase 2 trial. J Am Coll Cardiol. 2005 Nov 15;46(10):1803–1811.
   PubMed Web of Science ®Google Scholar
• Fukumoto Y, Mohri M, Inokuchi K, et al. Anti-ischemic effects of fasudil, a specific Rho-kinase inhibitor, in patients with stable effort angina. J Cardiovasc Pharmacol. 2007 Mar;49(3):117–121.
   PubMed Web of Science ®Google Scholar
• Shibuya M, Hirai S, Seto M, et al. Effects of fasudil in acute ischemic stroke: results of a prospective placebo-controlled double-blind trial. J Neurol Sci. 2005 Nov 15;238(1–2):31–39.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhang X, Wang S, et al. Effects of fasudil on patients with pulmonary hypertension associated with left ventricular heart failure with preserved ejection fraction: a prospective intervention study. Can Respir J. 2018;2018:3148259.
   PubMedGoogle Scholar
• Zammit VA. Carnitine acyltransferases: functional significance of subcellular distribution and membrane topology. Prog Lipid Res. 1999 May;38(3):199–224.
   PubMed Web of Science ®Google Scholar
• Paulson DJ, Schmidt MJ, Romens J, et al. Metabolic and physiological differences between zero-flow and low-flow myocardial ischemia: effects of L-acetylcarnitine. Basic Res Cardiol. 1984 Sep-Oct;79(5):551–561.
   PubMed Web of Science ®Google Scholar
• Paulson DJ, Traxler J, Schmidt M, et al. Protection of the ischaemic myocardium by L-propionylcarnitine: effects on the recovery of cardiac output after ischaemia and reperfusion, carnitine transport, and fatty acid oxidation. Cardiovasc Res. 1986 Jul;20(7):536–541.
   PubMed Web of Science ®Google Scholar
• Cui J, Das DK, Bertelli A, et al. Effects of L-carnitine and its derivatives on postischemic cardiac function, ventricular fibrillation and necrotic and apoptotic cardiomyocyte death in isolated rat hearts. Mol Cell Biochem. 2003 Dec;254(1–2):227–234.
   PubMed Web of Science ®Google Scholar
• Dhalla NS, Kolar F, Shah KR, et al. Effects of some L-carnitine derivatives on heart membrane ATPases. Cardiovasc Drugs Ther. 1991 Feb;5(Suppl 1):25–30.
   PubMedGoogle Scholar
• Lesnefsky EJ, He D, Moghaddas S, et al. Reversal of mitochondrial defects before ischemia protects the aged heart. Faseb J. 2006 Jul;20(9):1543–1545.
   PubMed Web of Science ®Google Scholar
• Loster H, Keller T, Grommisch J, et al. Effects of L-carnitine and its acetyl and propionyl esters on ATP and PCr levels of isolated rat hearts perfused without fatty acids and investigated by means of 31P-NMR spectroscopy. Mol Cell Biochem. 1999 Oct;200(1–2):93–102.
   PubMed Web of Science ®Google Scholar
• Bartels GL, Remme WJ, Pillay M, et al. Effects of L-propionylcarnitine on ischemia-induced myocardial dysfunction in men with angina pectoris. Am J Cardiol. 1994 Jul 15;74(2):125–130.
   PubMed Web of Science ®Google Scholar
• Lagioia R, Scrutinio D, Mangini SG, et al. Propionyl-L-carnitine: a new compound in the metabolic approach to the treatment of effort angina. Int J Cardiol. 1992 Feb;34(2):167–172.
   PubMed Web of Science ®Google Scholar
• Bartels GL, Remme WJ, Holwerda KJ, et al. Anti-ischaemic efficacy of L-propionylcarnitine–a promising novel metabolic approach to ischaemia? Eur Heart J. 1996 Mar;17(3):414–420.
   PubMed Web of Science ®Google Scholar
• Gullestad L, Jorgensen B, Bjuro T, et al. Postexercise ischemia is associated with increased neuropeptide Y in patients with coronary artery disease. Circulation. 2000 Aug 29;102(9):987–993.
   PubMed Web of Science ®Google Scholar
• Gullestad L, Bjuro T, Aaberge L, et al. The effect of a neuropeptide Y Y1 receptor antagonist in patients with angina pectoris. Eur Heart J. 2003 Jun;24(12):1120–1127.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang D, Ashraf M, et al. Combining neuropeptide Y and mesenchymal stem cells reverses remodeling after myocardial infarction. Am J Physiol Heart Circ Physiol. 2010 Jan;298(1):H275–86.
   PubMed Web of Science ®Google Scholar
• English KM, Steeds RP, Jones TH, et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. Circulation. 2000 Oct 17;102(16):1906–1911.
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Pugh PJ, Morris PD, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004 Aug;90(8):871–876.
   PubMed Web of Science ®Google Scholar
• Mathur A, Malkin C, Saeed B, et al. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol. 2009 Sep;161(3):443–449.
   PubMed Web of Science ®Google Scholar
• Testosterone Therapy on Angina Threshold and Atheroma in Patients With Chronic Stable Angina. [cited 2019 February 4. Available from: https://clinicaltrials.gov/ct2/show/NCT00131183.
   Google Scholar
• Hall G, Pripp U, Schenck-Gustafsson K, et al. Long-term effects of hormone replacement therapy on symptoms of angina pectoris, quality of life and compliance in women with coronary artery disease. Maturitas. 1998 Jan 12;28(3):235–242.
   PubMed Web of Science ®Google Scholar
• Pepine CJ, Ferdinand KC, Shaw LJ, et al. Emergence of nonobstructive coronary artery disease: a woman’s problem and need for change in definition on angiography. J Am Coll Cardiol. 2015 Oct 27;66(17):1918–1933.
   PubMed Web of Science ®Google Scholar
• Merz CN, Olson MB, McClure C, et al. A randomized controlled trial of low-dose hormone therapy on myocardial ischemia in postmenopausal women with no obstructive coronary artery disease: results from the National Institutes of Health/National Heart, Lung, and Blood Institute-sponsored Women’s Ischemia Syndrome Evaluation (WISE). Am Heart J. 2010 Jun;159(6):987e1–7.
   Web of Science ®Google Scholar
• Manson JE, Aragaki AK, Rossouw JE, et al. Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the Women’s Health Initiative randomized trials. Jama. 2017 Sep 12;318(10):927–938.
   PubMed Web of Science ®Google Scholar
• Burchfield JS, Dimmeler S. Role of paracrine factors in stem and progenitor cell mediated cardiac repair and tissue fibrosis. Fibrogenesis Tissue Repair. 2008 Oct 13;1(1):4.
   PubMedGoogle Scholar
• Hara H, Takeda N, Kondo M, et al. Discovery of a small molecule to increase cardiomyocytes and protect the heart after ischemic injury. JACC Basic Transl Sci. 2018 Oct;3(5):639–653.
   PubMedGoogle Scholar